Simultaneous Analysis of Aliskiren and Hydrochlorothiazide in their Combined Dosage Form and Spiked Human Plasma by HPTLC

Publication date: Available online 13 May 2016 Source:Journal of Taibah University for Science Author(s): Jui J. Pandya, Nejal M. Bhatt, Vijay D. Chavada, Primal Sharma, Mallika Sanyal, Pranav S. Shrivastav A simple, selective and precise method based on HPTLC has been developed for the simultaneous determination of aliskiren and hydrochlorothiazide in a fixed dose tablet formulation and human plasma. The chromatography was performed on silica gel 60 GF254 plates, with a mobile phase consisting of methanol-chloroform (6:4, v/v). Densitometric analysis of the analytes was carried out at 225nm. Under the optimized conditions, the R f values were 0.26±0.02 and 0.71± 0.02 and the regression plots were linear (r 2 ≥ 0.9997) in the concentration range of 1.00-10.0 and 0.10-1.00μg band−1 for aliskiren and hydrochlorothiazide respectively. The limit of detection and limit of quantitation of the validated method were 0.206 and 0.624μg band−1 for aliskiren and 0.015 and 0.046μg band−1 for hydrochlorothiazide. The % content found for aliskiren and hydrochlorothiazide in the tablet formulation was 99.2% and 101.3% respectively. For spiked plasma sample preparation, the analytes and nebivolol as an internal standard were extracted from 500μL plasma sample by solid phase extraction on LiChrosep® DVB-HL cartridges. The mean extraction recovery of aliskiren and hydrochlorothiazide from human plasma was 87.2% and 76.5% respectively. The stability of the anal...
Source: Journal of Taibah University for Science - Category: Science Source Type: research